The Philippines next generation sequencing market is projected to reach $177.96 million by 2036, at a CAGR of 12.5% from 2026 to 2036, up from an estimated $54.80 million in 2026. The market stood at $48.60 million in 2025. The growth of this market is primarily fueled by a funded population-wide genetic screening programme, expanding PhilHealth coverage of targeted cancer therapy, and a cancer burden weighted toward tumour types that depend on molecular characterisation. Additionally, emerging regulatory pathways such as ASEAN Abridged Processing lowering the barrier for suppliers already established elsewhere in the region, the arrival of automated platforms purpose-built for regional hospital deployment, and extension into agricultural and aquaculture applications are expected to create substantial growth opportunities for market participants.
Newborn bloodspot screening was integrated into the Philippine public health system by Republic Act 9288 in 2004, having first been introduced across 24 private and government hospitals in 1996. The Expanded Newborn Screening panel now covers 28 conditions using tandem mass spectrometry, and PhilHealth reimburses the test at PHP 2,950 under the Newborn Care Package, a sum that fully covers the cost at most accredited facilities - a positive screen, however, identifies the affected metabolic pathway but not the causative variant, and confirmation increasingly depends on sequencing. According to IARC GLOBOCAN, lung cancer recorded 23,728 new cases and 20,953 deaths in the Philippines in 2022, making it the second most common malignancy and the leading cause of cancer mortality in the country, with more than 70% of cases diagnosed at stage III or IV according to the hospital-based CARE PH registry project. PhilHealth expanded its Z Benefit Package in 2024 to cover targeted therapy for breast cancer at up to PHP 1 million per patient annually, roughly $18,000.
The key players operating in the Philippines next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China).
The Philippines next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Sequencing accounts for the largest share of the market in 2026. Data Analysis/Bioinformatics is expected to register the highest growth, reflecting the express regulation of clinical analysis software as a medical device under Administrative Order 2018-0002 and the requirement for validated clinical reporting.
Among all the applications, Clinical Applications hold the largest share of the market in 2026, driven by the absence of a publicly funded population research sequencing programme of the kind operating in several comparable markets. Within clinical applications, Reproductive Health holds the largest share, funded directly by patients, while Oncology is projected to register the highest growth.
Among all the end users, Hospitals, Clinical & Reference Laboratories account for the largest share of the market in 2026. Other end users, comprising principally agricultural, aquaculture, and plantation organisations, grow independently of clinical funding and access conditions.
The Philippines next generation sequencing market is consolidated and led by international suppliers, none of which manufactures within the country. Notably, only locally established Filipino companies may hold the Licence to Operate required to register and distribute medical devices in the country, so a foreign sequencing platform manufacturer must work through a Filipino entity that holds the licence in its own name.
Newborn bloodspot screening was integrated into the Philippine public health system by Republic Act 9288 in 2004, having first been introduced across 24 private and government hospitals in 1996. The Expanded Newborn Screening panel now covers 28 conditions using tandem mass spectrometry, and PhilHealth reimburses the test at PHP 2,950 under the Newborn Care Package, a sum that fully covers the cost at most accredited facilities - a positive screen, however, identifies the affected metabolic pathway but not the causative variant, and confirmation increasingly depends on sequencing. According to IARC GLOBOCAN, lung cancer recorded 23,728 new cases and 20,953 deaths in the Philippines in 2022, making it the second most common malignancy and the leading cause of cancer mortality in the country, with more than 70% of cases diagnosed at stage III or IV according to the hospital-based CARE PH registry project. PhilHealth expanded its Z Benefit Package in 2024 to cover targeted therapy for breast cancer at up to PHP 1 million per patient annually, roughly $18,000.
The key players operating in the Philippines next generation sequencing market are Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher Corporation (U.S.), Oxford Nanopore Technologies plc (U.K.), MGI Tech Co., Ltd. (China), BGI Genomics Co., Ltd. (China), Eurofins Scientific SE (Luxembourg), and Novogene Co., Ltd. (China).
The Philippines next generation sequencing market study presents historical market data value (2024, 2025), estimated current data (2026), and forecasts for 2036. This market is segmented by offering, application, and end user.
Among all the offerings, Sequencing accounts for the largest share of the market in 2026. Data Analysis/Bioinformatics is expected to register the highest growth, reflecting the express regulation of clinical analysis software as a medical device under Administrative Order 2018-0002 and the requirement for validated clinical reporting.
Among all the applications, Clinical Applications hold the largest share of the market in 2026, driven by the absence of a publicly funded population research sequencing programme of the kind operating in several comparable markets. Within clinical applications, Reproductive Health holds the largest share, funded directly by patients, while Oncology is projected to register the highest growth.
Among all the end users, Hospitals, Clinical & Reference Laboratories account for the largest share of the market in 2026. Other end users, comprising principally agricultural, aquaculture, and plantation organisations, grow independently of clinical funding and access conditions.
The Philippines next generation sequencing market is consolidated and led by international suppliers, none of which manufactures within the country. Notably, only locally established Filipino companies may hold the Licence to Operate required to register and distribute medical devices in the country, so a foreign sequencing platform manufacturer must work through a Filipino entity that holds the licence in its own name.
Key Questions Answered in the Report:
- What is the current revenue generated by the Philippines next generation sequencing market?
- At what rate is the Philippines NGS market demand projected to grow through 2036?
- What are the historical market sizes and growth rates of the Philippines NGS market?
- What are the major factors impacting the growth of this market? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of offering, application, and end user are expected to create major traction for the manufacturers in this market?
- Who are the major players in the Philippines NGS market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Philippines NGS market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Market Definition & Scope
2. Research Methodology
3. Executive Summary
4. Market Insights
5. Philippines NGS Market Assessment, By Offering
6. Philippines NGS Market Assessment, By Application
7. Philippines NGS Market Assessment, By End User
8. Competitive Landscape
9. 9. Company Profiles
10. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Illumina, Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN N.V.
- F. Hoffmann La Roche Ltd.
- Agilent Technologies, Inc.
- Revvity, Inc.
- Pacific Biosciences of California, Inc.
- Danaher Corporation
- Oxford Nanopore Technologies plc
- MGI Tech Co., Ltd.
- BGI Genomics Co., Ltd.
- Eurofins Scientific SE
- Novogene Co., Ltd. (China).
